File Download

There are no files associated with this item.

Supplementary

Conference Paper: Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET)

TitleBiomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET)
Authors
Yap, YSMasuda, NIto, YIshikawa, TKim, SJAruga, TToyama, TSaeki, TYamanaka, TSaito, MWatanabe, JTakahashi, MNakamura, SInoue, KSuarez-Vizcarra, JHe, WSolovieff, NSu, FChiu, WYJ
Issue Date2018
Citation
The European Society for Medical Oncology (ESMO) Asia 2018 Congress, Singapore, 23–25 November 2018 How to Cite?
DescriptionMini Oral session: Mini Oral - Breast cancerMini Oral session - 40O
Persistent Identifierhttp://hdl.handle.net/10722/263589

 

DC FieldValueLanguage
dc.contributor.authorYap, YS-
dc.contributor.authorMasuda, N-
dc.contributor.authorIto, Y-
dc.contributor.authorIshikawa, T-
dc.contributor.authorKim, SJ-
dc.contributor.authorAruga, T-
dc.contributor.authorToyama, T-
dc.contributor.authorSaeki, T-
dc.contributor.authorYamanaka, T-
dc.contributor.authorSaito, M-
dc.contributor.authorWatanabe, J-
dc.contributor.authorTakahashi, M-
dc.contributor.authorNakamura, S-
dc.contributor.authorInoue, K-
dc.contributor.authorSuarez-Vizcarra, J-
dc.contributor.authorHe, W-
dc.contributor.authorSolovieff, N-
dc.contributor.authorSu, F-
dc.contributor.authorChiu, WYJ-
dc.date.accessioned2018-10-22T07:41:23Z-
dc.date.available2018-10-22T07:41:23Z-
dc.date.issued2018-
dc.identifier.citationThe European Society for Medical Oncology (ESMO) Asia 2018 Congress, Singapore, 23–25 November 2018-
dc.identifier.urihttp://hdl.handle.net/10722/263589-
dc.descriptionMini Oral session: Mini Oral - Breast cancerMini Oral session - 40O-
dc.languageeng-
dc.relation.ispartofESMO (European Society for Medical On) ASIA 2018-
dc.titleBiomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET)-
dc.typeConference_Paper-
dc.identifier.emailChiu, WYJ: jwychiu@hku.hk-
dc.identifier.authorityChiu, WYJ=rp01917-
dc.identifier.hkuros295536-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats